guest ::
| Home > Publications database > Personalized brain models identify neurotransmitter receptor changes in Alzheimer’s disease > print |
| Home > Publications database > Personalized brain models identify neurotransmitter receptor changes in Alzheimer’s disease > print |
| 001 | 903186 | ||
| 005 | 20230123110541.0 | ||
| 024 | 7 | _ | |a 10.1093/brain/awab375 |2 doi |
| 024 | 7 | _ | |a 0006-8950 |2 ISSN |
| 024 | 7 | _ | |a 1460-2156 |2 ISSN |
| 024 | 7 | _ | |a 2128/31273 |2 Handle |
| 024 | 7 | _ | |a altmetric:114496357 |2 altmetric |
| 024 | 7 | _ | |a pmid:34605898 |2 pmid |
| 024 | 7 | _ | |a WOS:000788204200001 |2 WOS |
| 037 | _ | _ | |a FZJ-2021-04906 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Khan, Ahmed Faraz |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Personalized brain models identify neurotransmitter receptor changes in Alzheimer’s disease |
| 260 | _ | _ | |a Oxford |c 2022 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1654781511_30671 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Alzheimer’s disease involves many neurobiological alterations from molecular to macroscopic spatial scales, but we currently lack integrative, mechanistic brain models characterizing how factors across different biological scales interact to cause clinical deterioration in a way that is subject-specific or personalized. As important signalling molecules and mediators of many neurobiological interactions, neurotransmitter receptors are promising candidates for identifying molecular mechanisms and drug targets in Alzheimer's disease.We present a neurotransmitter receptor-enriched multifactorial brain model, which integrates spatial distribution patterns of 15 neurotransmitter receptors from post-mortem autoradiography with multiple in vivo neuroimaging modalities (tau, amyloid-β and glucose PET, and structural, functional and arterial spin labelling MRI) in a personalized, generative, whole-brain formulation.In a heterogeneous aged population (n = 423, ADNI data), models with personalized receptor-neuroimaging interactions showed a significant improvement over neuroimaging-only models, explaining about 70% (±20%) of the variance in longitudinal changes to the six neuroimaging modalities. In Alzheimer's disease patients (n = 25, ADNI data), receptor-imaging interactions explained up to 39.7% (P < 0.003, family-wise error-rate-corrected) of inter-individual variability in cognitive deterioration, via an axis primarily affecting executive function. Notably, based on their contribution to the clinical severity in Alzheimer’s disease, we found significant functional alterations to glutamatergic interactions affecting tau accumulation and neural activity dysfunction and GABAergic interactions concurrently affecting neural activity dysfunction, amyloid and tau distributions, as well as significant cholinergic receptor effects on tau accumulation. Overall, GABAergic alterations had the largest effect on cognitive impairment (particularly executive function) in our Alzheimer’s disease cohort (n = 25). Furthermore, we demonstrate the clinical applicability of this approach by characterizing subjects based on individualized ‘fingerprints’ of receptor alterations.This study introduces the first robust, data-driven framework for integrating several neurotransmitter receptors, multimodal neuroimaging and clinical data in a flexible and interpretable brain model. It enables further understanding of the mechanistic neuropathological basis of neurodegenerative progression and heterogeneity, and constitutes a promising step towards implementing personalized, neurotransmitter-based treatments. |
| 536 | _ | _ | |a 5251 - Multilevel Brain Organization and Variability (POF4-525) |0 G:(DE-HGF)POF4-5251 |c POF4-525 |f POF IV |x 0 |
| 536 | _ | _ | |a HBP SGA3 - Human Brain Project Specific Grant Agreement 3 (945539) |0 G:(EU-Grant)945539 |c 945539 |f H2020-SGA-FETFLAG-HBP-2019 |x 1 |
| 536 | _ | _ | |a HBP SGA2 - Human Brain Project Specific Grant Agreement 2 (785907) |0 G:(EU-Grant)785907 |c 785907 |f H2020-SGA-FETFLAG-HBP-2017 |x 2 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Adewale, Quadri |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Baumeister, Tobias R |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Carbonell, Felix |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Zilles, Karl |0 P:(DE-Juel1)131714 |b 4 |
| 700 | 1 | _ | |a Palomero-Gallagher, Nicola |0 P:(DE-Juel1)131701 |b 5 |u fzj |
| 700 | 1 | _ | |a Iturria-Medina, Yasser |0 P:(DE-HGF)0 |b 6 |e Corresponding author |
| 773 | _ | _ | |a 10.1093/brain/awab375 |g p. awab375 |0 PERI:(DE-600)1474117-9 |n 5 |p 1785–1804 |t Brain |v 145 |y 2022 |x 0006-8950 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/903186/files/awab375.pdf |
| 856 | 4 | _ | |y Published on 2021-10-04. Available in OpenAccess from 2022-10-04. |u https://juser.fz-juelich.de/record/903186/files/Khan%202021%20Personalized%20brain%20models%20identify%20neurotransmitter%20receptor%20changes%20in%20Alzheimer%27s%20disease%20--%20PREPRINT.pdf |
| 856 | 4 | _ | |y Published on 2021-10-04. Available in OpenAccess from 2022-10-04. |u https://juser.fz-juelich.de/record/903186/files/Khan_etal_2021_in%20press.pdf |
| 909 | C | O | |o oai:juser.fz-juelich.de:903186 |p openaire |p open_access |p driver |p VDB |p ec_fundedresources |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)131701 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5251 |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-29 |
| 915 | _ | _ | |a Embargoed OpenAccess |0 StatID:(DE-HGF)0530 |2 StatID |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-29 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2022-11-09 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-09 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BRAIN : 2021 |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-09 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-09 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b BRAIN : 2021 |d 2022-11-09 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-1-20090406 |k INM-1 |l Strukturelle und funktionelle Organisation des Gehirns |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-1-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|